Ausgabe 4/2009
Inhalt (8 Artikel)
Sunitinib paves the way for targeted therapies in neuroendocrine tumors
Eric Raymond, Sandrine Faivre, Pascal Hammel, Philippe Ruszniewski
Targeting insulin-like growth factor type 1 receptor in cancer therapy
Francesco Atzori, Tiffany A. Traina, Maria Teresa Ionta, Bruno Massidda
Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors
Austin Duffy, Shivaani Kummar
Targeted therapies in thyroid cancer
Jaume Capdevila, Jose Perez-Garcia, Gabriel Obiols, Josep Tabernero
Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors
Jaume Capdevila, Ramon Salazar
Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor
Ronan J. Kelly, Olivier Rixe
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
V. Sibaud, JP. Delord, C. Chevreau
Implications of KRAS mutation status for the treatment of metastatic colorectal cancer
Fortunato Ciardiello, Sabine Tejpar, Demetris Papamichael